- Home
- CELZ vs ENLV Comparison
CELZ vs ENLV Comparison
Compare CELZ & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CELZ | ENLV |
|---|---|---|
| Founded | 1998 | 2005 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6M | 4.0M |
| IPO Year | 2008 | 2014 |
Fundamental Metrics
Financial Performance| Metric | CELZ | ENLV |
|---|---|---|
| Price | $0.53 | $1.19 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 85.4K | ★ 208.5K |
| Earning Date | 11-06-2026 | 11-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.08 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.59 | $0.16 |
| 52 Week High | $4.72 | $7.64 |
Technical Indicators
Market Signals| Indicator | CELZ | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 31.24 | 51.93 |
| Support Level | N/A | $0.55 |
| Resistance Level | $0.93 | $2.89 |
| Average True Range (ATR) | 0.06 | 0.25 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 0.05 | 1.16 |
Price Performance
Historical ComparisonAbout CELZ Creative Medical Technology Holdings Inc.
Creative Medical Technology Holdings Inc is a commercial-stage biotechnology company focused on the advancement of regenerative therapies in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics. Its pipeline consists of AlloStem (CELZ-201-DDT); ImmCelz (CELZ-100), a personalized supercharged immune therapy platform; CELZ-201 CREATE-1, an intervention for the treatment of recent onset Type 1 Diabetes; AlloStemSpine for treatment of lower back pain; the Alova program to treat infertility as a result of premature ovarian failure; and other regenerative treatment programs and technologies like OvaStem, CaverStem, FemCelz, StemSpine, and others for the treatment of various indications related to sexual health, spine disc disease, kidney failure, liver failure, etc.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.